Plated

Plated is a biotechnology company pioneering the development of engineered platelets as a new modality for targeted drug delivery and cell therapy. The company's platform utilizes megakaryocyte engineering to produce platelets that can carry diverse payloads, including small molecules, proteins, and nucleic acids, to specific sites of disease. By exploiting the natural ability of platelets to home to areas of vascular damage, inflammation, and malignancy, Plated aims to create highly localized and potent treatments. Their approach addresses limitations of current delivery systems, offering potential breakthroughs in oncology, immunology, and regenerative medicine. The company is currently in the pre-clinical stage, advancing a pipeline of programs focused on high-unmet-need indications.